VAM
ANTH

Visium Asset Management’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

Visium Asset Management’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-25,000
Closed -$614K – 1095
2013
Q4 		$614K Buy
+25,000
New +$644K 0.01% 547

Other funds holding ANTH

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Visium Asset Management's ANTH Position: Q1 2014 in Review

Visium Asset Management sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q1 2014, closing a stake of 25,000 shares — an estimated $614K sold.

Visium Asset Management first reported a position in ANTH in Q4 2013 and held it in 1 quarter. The position peaked at $614K in Q4 2013. 35 funds tracked by Wall St. Rank hold ANTH as of Q1 2014.

  • Visium Asset Management reported no remaining Anthera Pharmaceuticals, Inc. position as of Q1 2014 after selling out during the quarter.
  • Visium Asset Management sold 25,000 Anthera Pharmaceuticals, Inc. shares in Q1 2014, an estimated $614K.
  • Visium Asset Management first reported a position in Anthera Pharmaceuticals, Inc. in Q4 2013 and held it in 1 quarter.
  • Visium Asset Management's Anthera Pharmaceuticals, Inc. position peaked at $614K in Q4 2013.
  • 35 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q1 2014.

Based on Visium Asset Management's 13F filing for Q1 2014, filed 15 May 2014.